IL-28B/IFN-λ3 Protein, Human,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Human
Synonyms	Interferon lambda-3; IFN-lambda-3; Cytokine Zcyto22; Interleukin-28B (IL-28B); Interleukin-28C (IL-28C);
Accession	Q8IZI9
Amino Acid Sequence	Val22-Val196
Expression System	E.coli
Molecular Weight	18 kDa (Reducing)
Purity	>95% by SDS-PAGE; >90% by HPLC.
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	No Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, pH7.4
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. ·3 months, -20 to -80℃ under sterile conditions after reconstitution. ·1 week, 2 to 8℃ under sterile conditions after reconstitution. ·Please avoid repeated freeze-thaw cycles.
Reference	Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.

Background

Interferon lambda 3 (IFN-λ3), also known as interleukin-28B (IL-28B), is a type III interferon that plays a crucial role in the innate immune response against viral infections. IFN-λ3 is produced in response to viral stimuli and exerts potent antiviral effects by inducing the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and spread. Similar to other type III interferons, IFN-λ3 signals through the IFN-λ receptor complex, which consists of IL-10R2 and IL-28Rα subunits, leading to the activation of downstream signaling pathways involved in antiviral defense. IFN-λ3 has been implicated in the immune response to various viral infections, including hepatitis C virus (HCV) and influenza virus, and is considered a promising therapeutic target for the treatment of viral diseases.